Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 12/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.43 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL739476 | 0.92 | HRH1 (0.43) | HRH1KCNH2CYP2D6PROKR1CHRM1 | |
| SCHEMBL742873 | 0.90 | HRH1 (0.41) | HRH1KCNH2CYP2D6PROKR1CHRM1 | |
| SCHEMBL742872 | 0.90 | HRH1 (0.41) | HRH1KCNH2CYP2D6PROKR1CHRM1 | |
| SCHEMBL762597 | 0.89 | KCNH2 (0.45) | HRH1KCNH2CYP2D6PROKR1CHRM1 | |
| SCHEMBL742749 | 0.88 | HRH1 (0.43) | HRH1KCNH2CYP2D6PROKR1CHRM1 | |
| SCHEMBL741907 | 0.88 | HRH1 (0.41) | HRH1KCNH2CYP2D6CHRM1 | |
| SCHEMBL742216 | 0.88 | KCNH2 (0.44) | HRH1KCNH2CYP2D6PROKR1CHRM1 | |
| SCHEMBL742217 | 0.88 | KCNH2 (0.44) | HRH1KCNH2CYP2D6PROKR1CHRM1 | |
| SCHEMBL740379 | 0.88 | HRH1 (0.44) | HRH1KCNH2CYP2D6CHRM1 | |
| SCHEMBL739313 | 0.88 | HRH1 (0.44) | HRH1KCNH2CYP2D6CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024146917-A1 | DRUG PAD | GH RESEARCH IRELAND LTD (IE) | 2024-07-11 | — | — | WO | claimed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | claimed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2024146917-A1 | DRUG PAD | GH RESEARCH IRELAND LTD (IE) | 2024-07-11 | — | — | WO | disclosed |
| CN-118234491-A | Hallucinogen-fatty acid combinations | 明德赛特制药公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | disclosed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20240000795-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. | 2024-01-04 | — | — | US | disclosed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023129976-A1 | SALT AND SOLID FORMS OF KETANSERIN | TERRAN BIOSCIENCES, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| CN-111798937-B | Method for establishing metabonomics database of wolfberry tissue and application thereof | 宁夏农林科学院枸杞工程技术研究所 | 2021-10-01 | — | — | CN | disclosed |
| CN-111798937-A | Method for establishing metabonomics database of wolfberry tissue and application thereof | 宁夏农林科学院枸杞工程技术研究所 | 2020-10-20 | — | — | CN | disclosed |
| CN-111398476-A | Method for detecting 5-MeO-DIPT in urine | 司法鉴定科学研究院 | 2020-07-10 | — | — | CN | disclosed |
| US-8138168-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000795-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | HTR2A, HTR1A, HTR2C | HRH1 504/4885KCNH2 1920/4885CYP2D6 1808/4885 |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR3A | HRH1 575/4885KCNH2 2330/4885CYP2D6 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.